Back
Sage Therapeutics 10K Form
Sell
16
SAGE
Sage Therapeutics
Last Price:
13.34
Seasonality Move:
10.04%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive SAGE News And Ratings
See the #1 stock for the next 7 days that we like better than SAGE
SAGE Financial Statistics
Sales & Book Value
| Annual Sales: | $86.46M |
|---|---|
| Cash Flow: | $-119.41M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $13.32 |
| Price / Book: | 0.98 |
Profitability
| EPS (TTM): | -9.05000 |
|---|---|
| Net Income (TTM): | $-541.49M |
| Gross Margin: | $84.3M |
| Return on Equity: | -54.3% |
| Return on Assets: | -49.3% |
Sage Therapeutics Earnings Forecast
Key Sage Therapeutics Financial Ratios
- The Gross Profit Margin over the past 11 years for SAGE is 97.50%.
- The Selling, General & Administrative Expenses for SAGE have been equal to 317.53% of Gross Profit Margin.
- The Research & Development expenses have been 412.05% of Revenue.
- The Interest Expense is 0.00% of Operating Income.
- Per Share Earnings over the last 12 years have been positive in 1 years.
Sage Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | SAGE |
| CUSIP: | 78667J |
| Website: | sagerx.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 10.51 |
| Quick Ratio: | 10.11 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
SAGE Technical Analysis vs Fundamental Analysis
Sell
16
Sage Therapeutics (SAGE)
is a Sell
Is Sage Therapeutics a Buy or a Sell?
-
Sage Therapeutics stock is rated a Sell
The current Sage Therapeutics [SAGE] share price is $13.03. The Score for SAGE is 16, which is 68% below its historic median score of 50, and infers higher risk than normal.